PubRank
Search
About
M Fey
Author PubWeight™ 38.07
‹?›
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI.
Eur J Cancer
1998
3.03
2
A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group.
Blood
1999
2.98
3
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
J Clin Oncol
2000
1.92
4
Identifying breast cancer patients at high risk for bone metastases.
J Clin Oncol
2000
1.91
5
Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
Leukemia
2006
1.77
6
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII.
J Clin Oncol
2003
1.75
7
Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer.
J Clin Oncol
2001
1.49
8
Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial.
Br J Haematol
2000
1.37
9
Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK).
Ann Oncol
2005
1.36
10
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.
Leukemia
2012
1.33
11
Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group.
Leukemia
2000
1.31
12
First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88.
Ann Oncol
1996
1.15
13
Endocytosis and shedding of the decay accelerating factor on human polymorphonuclear cells.
J Immunol
1989
1.13
14
Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy.
J Clin Oncol
2004
1.13
15
Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience.
Leukemia
2003
1.13
16
Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group.
J Clin Oncol
2004
1.03
17
Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Br J Cancer
2001
1.02
18
Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial.
Leukemia
2003
0.94
19
Transmission of malaria by renal transplantation.
Transplantation
1985
0.93
20
Changes in the lipids of human milk from 2 to 16 weeks postpartum.
J Pediatr Gastroenterol Nutr
1982
0.92
21
Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
J Clin Oncol
1994
0.89
22
Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience.
Leukemia
2005
0.89
23
Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors.
Cancer Res
1991
0.89
24
Structural features of the human C3 gene: intron/exon organization, transcriptional start site, and promoter region sequence.
Biochemistry
1991
0.87
25
Evaluation of fluoride release from commercially available fluoride varnishes.
J Am Dent Assoc
2001
0.86
26
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas.
Ann Oncol
2006
0.81
27
Relationship between cleaved L-selectin levels and the outcome of acute myeloid leukemia.
Blood
1998
0.80
28
Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The European experience. European APL Group.
Leuk Lymphoma
1995
0.78
29
Hyperoxia effects on lung vascular circulating and marginated leukocytes in the rat.
Bull Eur Physiopathol Respir
1985
0.78
30
Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias.
Br J Haematol
1995
0.76
31
Use of triple-lumen subclavian catheters for administration of total parenteral nutrition.
JPEN J Parenter Enteral Nutr
1993
0.75
32
Prolonged follow-up confirms that all-trans retinoic acid followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia. The French APL Group.
Blood
1994
0.75
33
[Acute effects of N-chloropropyl-amphetamine (Ro 4-5282) on the hemodynamics of human macro- and microcirculation].
Arzneimittelforschung
1972
0.75
34
High-dose cytosine arabinoside therapy for refractory leukemia.
Blood
1984
0.75
35
Acute myeloblastic leukemia in adult patients: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Ann Oncol
2007
0.75
36
[Results of the heart infarct treatment before and after installation of an intensive care unit in a regional hospital].
Schweiz Rundsch Med Prax
1972
0.75
37
[Adult anemia].
Schweiz Rundsch Med Prax
1984
0.75
38
Pharmacokinetics of isosorbide-5-nitrate during haemodialysis and peritoneal dialysis.
Eur J Clin Pharmacol
1987
0.75